人型支原体拓扑异构酶IV parC和parE基因的克隆及核苷酸序列
Cloning and nucleotide sequences of the topoisomerase IV parC and parE genes of Mycoplasma hominis.
作者信息
Bébéar C M, Charron A, Bové J M, Bébéar C, Renaudin J
机构信息
Laboratoire de Bactériologie, Université Bordeaux 2, 33076 Bordeaux Cedex, France.
出版信息
Antimicrob Agents Chemother. 1998 Aug;42(8):2024-31. doi: 10.1128/AAC.42.8.2024.
Abstract
The topoisomerase IV parC and parE genes from the wall-less organism Mycoplasma hominis PG21 were cloned and sequenced. The coupled genes are located far from the DNA gyrase genes gyrA and gyrB. They encode proteins of 639 and 866 amino acids, respectively. As expected, the encoded ParE and ParC proteins exhibit higher homologies with the topoisomerase IV subunits of the gram-positive bacteria Staphylococcus aureus and Streptococcus pneumoniae than with their Escherichia coli counterparts. The conserved regions include the Tyr residue of the active site and the region involved in quinolone resistance (quinolone resistance-determining region [QRDR]) in ParC and the ATP-binding site and the QRDR in ParE.
摘要
对无细胞壁的人型支原体PG21的拓扑异构酶IV的parC和parE基因进行了克隆和测序。这两个耦合基因的位置远离DNA促旋酶基因gyrA和gyrB。它们分别编码含639个和866个氨基酸的蛋白质。正如预期的那样，所编码的ParE和ParC蛋白与革兰氏阳性菌金黄色葡萄球菌和肺炎链球菌的拓扑异构酶IV亚基的同源性高于与大肠杆菌对应亚基的同源性。保守区域包括ParC中活性位点的Tyr残基和参与喹诺酮耐药性的区域（喹诺酮耐药决定区[QRDR]）以及ParE中的ATP结合位点和QRDR。
相似文献
1
Cloning and nucleotide sequences of the topoisomerase IV parC and parE genes of Mycoplasma hominis.人型支原体拓扑异构酶IV parC和parE基因的克隆及核苷酸序列
Antimicrob Agents Chemother. 1998 Aug;42(8):2024-31. doi: 10.1128/AAC.42.8.2024.
2
Cloning and nucleotide sequence of the DNA gyrase (gyrA) gene from Mycoplasma hominis and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin.人型支原体DNA促旋酶（gyrA）基因的克隆、核苷酸序列分析及体外筛选的曲伐沙星耐药突变株的特性研究
Antimicrob Agents Chemother. 2000 Oct;44(10):2719-27. doi: 10.1128/AAC.44.10.2719-2727.2000.
3
Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.肺炎链球菌编码DNA拓扑异构酶IV的parC和parE基因的克隆与特性分析：在氟喹诺酮耐药性中的作用
J Bacteriol. 1996 Jul;178(14):4060-9. doi: 10.1128/jb.178.14.4060-4069.1996.
4
Mutations in the gyrA, parC, and parE genes associated with fluoroquinolone resistance in clinical isolates of Mycoplasma hominis.人型支原体临床分离株中与氟喹诺酮耐药相关的gyrA、parC和parE基因的突变
Antimicrob Agents Chemother. 1999 Apr;43(4):954-6. doi: 10.1128/AAC.43.4.954.
5
Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.金黄色葡萄球菌DNA拓扑异构酶IV的克隆及一级结构：氟喹诺酮类药物的主要作用靶点
Mol Microbiol. 1994 Aug;13(4):641-53. doi: 10.1111/j.1365-2958.1994.tb00458.x.
6
Alterations in topoisomerase IV and DNA gyrase in quinolone-resistant mutants of Mycoplasma hominis obtained in vitro.体外获得的人型支原体喹诺酮耐药突变体中拓扑异构酶IV和DNA促旋酶的改变。
Antimicrob Agents Chemother. 1998 Sep;42(9):2304-11. doi: 10.1128/AAC.42.9.2304.
7
8
[Role of mutations in parC and gyrA in forming resistance of Mycoplasma hominis to fluoroquinolones].[人型支原体中parC和gyrA基因突变在形成对氟喹诺酮类药物抗性中的作用]
Mol Gen Mikrobiol Virusol. 1999(4):19-24.
9
Mutations in the gyrB, parC, and parE genes of quinolone-resistant isolates and mutants of Edwardsiella tarda.产酸克雷伯菌喹诺酮类耐药株和突变株中 gyrB、parC 和 parE 基因突变。
J Microbiol Biotechnol. 2010 Dec;20(12):1735-43.
10
Characterization of genes encoding topoisomerase IV of Mycoplasma genitalium.生殖支原体拓扑异构酶IV编码基因的特征分析。
Gene. 1996 Feb 2;168(1):77-80. doi: 10.1016/0378-1119(95)00718-0.
引用本文的文献
1
Functional analysis of three topoisomerases that regulate DNA supercoiling levels in Chlamydia.对三种调节衣原体DNA超螺旋水平的拓扑异构酶的功能分析。
Mol Microbiol. 2016 Feb;99(3):484-96. doi: 10.1111/mmi.13241. Epub 2015 Nov 13.
2
Genomic Investigations unmask Mycoplasma amphoriforme, a new respiratory pathogen.
Clin Infect Dis. 2015 Feb 1;60(3):381-8. doi: 10.1093/cid/ciu820. Epub 2014 Oct 23.
3
Association of mutation patterns in GyrA and ParC genes with quinolone resistance levels in lactic acid bacteria.乳酸杆菌中GyrA和ParC基因突变模式与喹诺酮耐药水平的关联
J Antibiot (Tokyo). 2015 Feb;68(2):81-7. doi: 10.1038/ja.2014.113. Epub 2014 Sep 10.
4
Mutations in 23S rRNA account for intrinsic resistance to macrolides in Mycoplasma hominis and Mycoplasma fermentans and for acquired resistance to macrolides in M. hominis.23S rRNA中的突变导致人型支原体和解脲脲原体对大环内酯类药物产生固有耐药性，以及人型支原体对大环内酯类药物产生获得性耐药性。
Antimicrob Agents Chemother. 2002 Oct;46(10):3142-50. doi: 10.1128/AAC.46.10.3142-3150.2002.
5
Characterization of mutations in DNA gyrase and topoisomerase IV Involved in quinolone resistance of Mycoplasma gallisepticum mutants obtained in vitro.体外获得的鸡毒支原体突变体中参与喹诺酮耐药性的DNA促旋酶和拓扑异构酶IV突变的特征分析
Antimicrob Agents Chemother. 2002 Feb;46(2):590-3. doi: 10.1128/AAC.46.2.590-593.2002.
6
Cloning and nucleotide sequence of the DNA gyrase (gyrA) gene from Mycoplasma hominis and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin.人型支原体DNA促旋酶（gyrA）基因的克隆、核苷酸序列分析及体外筛选的曲伐沙星耐药突变株的特性研究
Antimicrob Agents Chemother. 2000 Oct;44(10):2719-27. doi: 10.1128/AAC.44.10.2719-2727.2000.
7
Diagnosis of quinolone-resistant Coxiella burnetii strains by PCR-RFLP.通过聚合酶链反应-限制性片段长度多态性分析诊断对喹诺酮耐药的伯氏考克斯氏体菌株
J Clin Lab Anal. 2000;14(2):59-63. doi: 10.1002/(SICI)1098-2825(2000)14:2<59::AID-JCLA4>3.0.CO;2-P.
8
Sparfloxacin selects gyrase mutations in first-step Mycoplasma hominis mutants, whereas ofloxacin selects topoisomerase IV mutations.司帕沙星在人型支原体第一步突变体中选择gyrase突变，而氧氟沙星选择拓扑异构酶IV突变。
Antimicrob Agents Chemother. 1999 Oct;43(10):2493-6. doi: 10.1128/AAC.43.10.2493.
9
Mutations in the gyrA, parC, and parE genes associated with fluoroquinolone resistance in clinical isolates of Mycoplasma hominis.人型支原体临床分离株中与氟喹诺酮耐药相关的gyrA、parC和parE基因的突变
Antimicrob Agents Chemother. 1999 Apr;43(4):954-6. doi: 10.1128/AAC.43.4.954.
本文引用的文献
1
Alterations in topoisomerase IV and DNA gyrase in quinolone-resistant mutants of Mycoplasma hominis obtained in vitro.体外获得的人型支原体喹诺酮耐药突变体中拓扑异构酶IV和DNA促旋酶的改变。
Antimicrob Agents Chemother. 1998 Sep;42(9):2304-11. doi: 10.1128/AAC.42.9.2304.
2
The complete genome sequence of the gastric pathogen Helicobacter pylori.胃病原体幽门螺杆菌的全基因组序列。
Nature. 1997 Aug 7;388(6642):539-47. doi: 10.1038/41483.
3
Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae.肺炎链球菌中赋予氟喹诺酮耐药性的parE基因突变特征分析。
Antimicrob Agents Chemother. 1997 May;41(5):1166-7. doi: 10.1128/AAC.41.5.1166.
4
Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.司帕沙星对肺炎链球菌中DNA回旋酶的靶向作用：喹诺酮类药物对回旋酶或拓扑异构酶IV的选择性靶向作用
Antimicrob Agents Chemother. 1997 Feb;41(2):471-4. doi: 10.1128/AAC.41.2.471.
5
Characterization of Mycoplasma hominis mutations involved in resistance to fluoroquinolones.人型支原体对氟喹诺酮类耐药相关突变的特征分析
Antimicrob Agents Chemother. 1997 Feb;41(2):269-73. doi: 10.1128/AAC.41.2.269.
6
Bacterial diversity based on type II DNA topoisomerase genes.基于II型DNA拓扑异构酶基因的细菌多样性
Annu Rev Genet. 1996;30:79-107. doi: 10.1146/annurev.genet.30.1.79.
7
Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of the parE gene encoding a subunit of topoisomerase IV.大肠杆菌喹诺酮耐药位点nfxD是编码拓扑异构酶IV一个亚基的parE基因的突变等位基因。
Antimicrob Agents Chemother. 1997 Jan;41(1):175-9. doi: 10.1128/AAC.41.1.175.
8
New genes in the 170 degrees region of the Bacillus subtilis genome encode DNA gyrase subunits, a thioredoxin, a xylanase and an amino acid transporter.枯草芽孢杆菌基因组170度区域的新基因编码DNA促旋酶亚基、一种硫氧还蛋白、一种木聚糖酶和一种氨基酸转运蛋白。
Microbiology (Reading). 1996 Nov;142 ( Pt 11):3097-101. doi: 10.1099/13500872-142-11-3097.
9
Complete sequence analysis of the genome of the bacterium Mycoplasma pneumoniae.肺炎支原体细菌基因组的全序列分析。
Nucleic Acids Res. 1996 Nov 15;24(22):4420-49. doi: 10.1093/nar/24.22.4420.
10
Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro.gyrA和parC基因突变对体内外获得的肺炎链球菌突变体氟喹诺酮耐药性的影响。
Antimicrob Agents Chemother. 1996 Nov;40(11):2505-10. doi: 10.1128/AAC.40.11.2505.
Zotero 插件